Th1*(pg/ml) | Responders to NAC | LLABCs: Baseline Levels (n = 30) | HFDs (n = 8) | Th2** (pg/ml) | Responders to NAC | LLABCs: Baseline Levels (n = 30) | HFDs (n = 8) |
---|---|---|---|---|---|---|---|
IL-1β | GR *** | 32.50 ± 10.00 (8 fold reduction) (P = 0.002) | 260.00 ± 110.00 | IL-4 | GR | 195.64 ± 5.68 (12 fold increase) (P = 0.001) | 16.00 ± 9.00 |
 | PR *** | 3.33 ± 0.78 (78 fold reduction)(P = 0.001) |  |  | PR | 197.50 ± 7.50 (12 fold increase) (P = 0.001) |  |
IL-2 | GR | 702.57 ± 240.00 (2 fold reduction) (P = 0.004) | 1400.00 ± 400.00 | IL-5 | GR | 156.12 ± 19.89 (6 fold increase) (P = 0.004) | 26.93 ± 8.00 |
 | PR | 293.33 ± 29.63 (5 fold reduction) (P = 0.001) |  |  | PR | 602.24 ± 78.58 (24 fold increase)(P = 0.004) |  |
 |  | reduction) (P = 0.001) |  |  |  |  |  |
INF-γ | GR | 144.76 ± 16.76 (12 fold reduction) (P = 0.009) | 1874.89 ± 156.15 | IL-10 | GR | 34.42 ± 36.84 (1.7 fold increase) (NS) | 20.00 ± 8.00 |
 | PR | 78.54 ± 21.42 (24 fold reduction) (P = 0.002) |  |  | PR | 30.00 ± 6.52 (1.5 fold increase) (NS) |  |
TNF-α | GR | 168.78 ± 12.36 (1.3 fold reduction) (P = 0.006) | 224.30 ±35.00 | Th17*** (pg/ml) | Responders to NAC | LLABCs: Baseline Levels (n = 30) | HFDs (n = 8) |
 | PR | 7.71 ± 3.83 (29 fold reduction) (P = 0.001) |  | IL-17A FOXP3 - ) | GR | 1.95 ± 0.25 2.8 fold increase) P = 0.003) | 0.70 ± 0.25 |
 |  |  |  |  | PR | 3.80 ± 0.80 5.4 fold increase) (P = 0.001) |  |
 |  |  |  | IL-17A (FOXP3 + ) | GR | 0.04 ± 0.02 (3.8 fold increase) (P = 0.023) | 0.01 ± 0.01 |
 |  |  |  |  | PR | 0.05 ± 0.01 (5 fold increase) (P = 0.018) |  |